Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says

Executive Summary

AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call

You may also be interested in...



Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty

An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry

Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty

An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry

PPI Coverage Adjusts To Prilosec OTC; Wyeth Sees Growth For Protonix In ‘04

Wyeth expects Protonix (pantoprazole) to remain a readily available "tier 2" agent in most health plans during 2004 despite the changing dynamics in the proton pump inhibitor market

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel